Open AccessThe presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy
Author(s) -
Sung Gon Park,
Kang Hee Shim,
Seol Ho Choo,
Sejoong Kim,
Sun Il Kim
Publication year - 2021
Publication title -
investigative and clinical urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.653
H-Index - 14
eISSN - 2466-054X
pISSN - 2466-0493
DOI - 10.4111/icu.20200545
Subject(s) - medicine , biopsy , prostate cancer , prostatectomy , prostate specific antigen , urology , prostate biopsy , biochemical recurrence , prostate , cancer
In large scale prospective studies, prostate-specific antigen (PSA)-screening not only decreased prostate cancer mortality, but also reduced biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP). We investigated the independent effect of the presence of PSA checked more than 1 year before diagnostic biopsy on the prognosis of patients undergoing RP in a real world setting without PSA-screening.